UK markets closed

Edwards Lifesciences Corporation (EW)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
78.14-0.07 (-0.09%)
At close: 04:00PM EST
77.69 -0.45 (-0.58%)
After hours: 07:56PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 48.35B
Enterprise value 47.30B
Trailing P/E 33.71
Forward P/E 31.25
PEG ratio (5-yr expected) 3.65
Price/sales (ttm)9.16
Price/book (mrq)7.78
Enterprise value/revenue 8.82
Enterprise value/EBITDA 23.94

Trading information

Stock price history

Beta (5Y monthly) 1.01
52-week change 3-28.44%
S&P500 52-week change 3-9.85%
52-week high 3131.10
52-week low 367.13
50-day moving average 375.68
200-day moving average 389.88

Share statistics

Avg vol (3-month) 34.89M
Avg vol (10-day) 32.69M
Shares outstanding 5618.26M
Implied shares outstanding 6N/A
Float 8612.67M
% held by insiders 10.81%
% held by institutions 184.82%
Shares short (12 Jan 2023) 413.93M
Short ratio (12 Jan 2023) 43.87
Short % of float (12 Jan 2023) 42.27%
Short % of shares outstanding (12 Jan 2023) 42.25%
Shares short (prior month 14 Dec 2022) 413.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 331 May 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 27.20%
Operating margin (ttm)31.82%

Management effectiveness

Return on assets (ttm)12.70%
Return on equity (ttm)24.81%

Income statement

Revenue (ttm)5.36B
Revenue per share (ttm)8.63
Quarterly revenue growth (yoy)0.70%
Gross profit (ttm)3.98B
Net income avi to common (ttm)1.46B
Diluted EPS (ttm)2.32
Quarterly earnings growth (yoy)1.00%

Balance sheet

Total cash (mrq)1.74B
Total cash per share (mrq)2.81
Total debt (mrq)686.8M
Total debt/equity (mrq)11.05
Current ratio (mrq)3.83
Book value per share (mrq)10.04

Cash flow statement

Operating cash flow (ttm)1.31B
Levered free cash flow (ttm)947.56M